Abstract：
OBJECTIVE: This review aims to analyse the recurrence rate in BRAFv600e+ and BRAFv600e- ameloblastomas and explore its association with clinicopathological variables.
METHODS: A comprehensive search was conducted using databases including PubMed, Embase, Cochrane Central Register of Controlled Trials, Clinicaltrials.gov, Google Scholar and grey literature, without any limitation on start date or language up to 20 June 2023. A random effect meta-analysis was conducted and Metaregression analyses were performed based on available clinicopathological factors.
RESULTS: Fifteen studies met the criteria for meta-analysis of outcomes. There was no significant difference in overall recurrence rates between the two groups (risk difference = 0.001, p-value = 0.987). Increasing male:female ratio in the BRAFv600e+ group was associated with a lower reported recurrence, suggesting a higher recurrence rate in females. The odds of having mandibular lesion were four times higher in BRAFv600e+ cases compared to BRAFv600e- cases (confidence interval: 2.121-7.870, p < 0.001, I2 = 28.37%).
CONCLUSIONS: Within the BRAFv600e+ group, females showed a higher reported recurrence rate. This specific clinical group may benefit from BRAFv600e mutation investigation and potential upscaled surgical treatment and additional BRAF inhibitor therapy, which needs validation in future studies.
METHODS: A comprehensive search was conducted using databases including PubMed, Embase, Cochrane Central Register of Controlled Trials, Clinicaltrials.gov, Google Scholar and grey literature, without any limitation on start date or language up to 20 June 2023. A random effect meta-analysis was conducted and Metaregression analyses were performed based on available clinicopathological factors.
RESULTS: Fifteen studies met the criteria for meta-analysis of outcomes. There was no significant difference in overall recurrence rates between the two groups (risk difference = 0.001, p-value = 0.987). Increasing male:female ratio in the BRAFv600e+ group was associated with a lower reported recurrence, suggesting a higher recurrence rate in females. The odds of having mandibular lesion were four times higher in BRAFv600e+ cases compared to BRAFv600e- cases (confidence interval: 2.121-7.870, p < 0.001, I2 = 28.37%).
CONCLUSIONS: Within the BRAFv600e+ group, females showed a higher reported recurrence rate. This specific clinical group may benefit from BRAFv600e mutation investigation and potential upscaled surgical treatment and additional BRAF inhibitor therapy, which needs validation in future studies.
摘要：
目的：本综述旨在分析BRAFv600e+和BRAFv600e-成釉细胞瘤的复发率，并探讨其与临床病理变量的关系。
方法：使用包括PubMed，Embase,Cochrane中央控制试验登记册,Clinicaltrials.gov,谷歌学者和灰色文学，在2023年6月20日之前对开始日期或语言没有任何限制。进行了随机效应荟萃分析，并根据可用的临床病理因素进行了元回归分析。
结果：15项研究符合结局荟萃分析的标准。两组之间的总复发率没有显着差异（风险差异=0.001，p值=0.987）。在BRAFv600e+组中增加的男性：女性比例与较低的报告复发相关。提示女性复发率较高。与BRAFv600e病例相比，BRAFv600e病例发生下颌骨病变的几率是BRAFv600e病例的四倍（置信区间：2.121-7.870，p<0.001，I2=28.37％）。
结论：在BRAFv600e+组中，女性报告复发率较高.这个特定的临床组可能受益于BRAFv600e突变研究和潜在的扩大手术治疗和额外的BRAF抑制剂治疗，这需要在未来的研究中进行验证。
方法：使用包括PubMed，Embase,Cochrane中央控制试验登记册,Clinicaltrials.gov,谷歌学者和灰色文学，在2023年6月20日之前对开始日期或语言没有任何限制。进行了随机效应荟萃分析，并根据可用的临床病理因素进行了元回归分析。
结果：15项研究符合结局荟萃分析的标准。两组之间的总复发率没有显着差异（风险差异=0.001，p值=0.987）。在BRAFv600e+组中增加的男性：女性比例与较低的报告复发相关。提示女性复发率较高。与BRAFv600e病例相比，BRAFv600e病例发生下颌骨病变的几率是BRAFv600e病例的四倍（置信区间：2.121-7.870，p<0.001，I2=28.37％）。
结论：在BRAFv600e+组中，女性报告复发率较高.这个特定的临床组可能受益于BRAFv600e突变研究和潜在的扩大手术治疗和额外的BRAF抑制剂治疗，这需要在未来的研究中进行验证。
